SABS - SAB Biotherapeutics GAAP EPS of -$0.14
2023-08-22 05:21:59 ET
More on SAB Biotherapeutics
- SAB Bio posts positive data from phase 3 trial of SAB-185 in patients with COVID-19
- SAB Biotherapeutics surges ~85% on FDA fast track tag for influenza drug SAB-176
- SAB Biotherapeutics gets additional $8.2M in funding in closeout DoD contract
- SAB Biotherapeutics announces $7.9M private placement of stock
- Seeking Alpha’s Quant Rating on SAB Biotherapeutics
- Earnings data for SAB Biotherapeutics
For further details see:
SAB Biotherapeutics GAAP EPS of -$0.14